sarsia innovation as sarsia innovation as the ‘bergen model’ for commercialisation spans the...
TRANSCRIPT
Sarsia Innovation AS
Sarsia Innovation asThe ‘Bergen Model’ for commercialisation spans the process from identification of a
promising research project on to company growth and international expansion.
Brussels, 11 September 2006
Hans Hekland CEO ”
2
How is it done at University of Bergen?
• Sarsia Innovation
– Who is behind and why?
– Track record
• The early-stage gap
– Commercialisation chain
– What's missing an why?
• The development of the Bergen model commercialisation
– Sarsia faces the early-stage gap
– The ideal model ?
– The different players and their interface
– Different shareholders for different phase and corporate government
– Synergies
3
Sarsia Innovation as
Industrial Development Corporation of Norway
Institutional investors
Sarsia was established in 2001 on the initiative of :
Bergen High-technology
Centre
4
Sarsia Innovation AS shall invest in research-based projects, and develop them into businesses of quality and size interesting for venture capital and industry investors.
Sarsia Innovation – track record
155 Commercialisation projects
23 Start-ups
3 Trade sales
5 VC stage financing rounds
1 IPO
Established ;Sarsia Life Science Fund (M€ 45)
Sarsia Seed Fund (M€ 45)
5
University “spin-outs” faces the early-stage gap
new company growth stageseed stageproject
Technology Transfer Office Venture Capital
Business support and investment capital is provided by different commercialisation outfits all focusing at a specific stage of company development.
6
Why gap?
The venture capitalist looks for ;
Superior returns
– Break through technologies
– Crisp value proposition
– Experienced Management
– Clear exit options
7
Superior returns ?
IRR (Thomson Venture Economics 12 Oct.2004)
– European VC-fund:–Average 7,2%
–Upper half 13,8%
–Upper quarter 19,7%
– European Buy-out fond:–Average 12,2%
–Upper half 22,2%
–Upper quarter 30,2%
European early stage return; (EVCA 2003)
–10yrs = 1,3%
–5yrs = -11,8%
0
50
100
150
200
250
300
Seed Seed VC VC
Later stage; less risky, less work,quick exit
8
University “spin-outs” often fails on
Business concept /value proposition
Lack of management resources (int. network)
Unclear funding needs and milestones
Unclear exit (few options)
Inventors unrealistic expectations of value.
9
Sarsia Innovation faces the early-stage gap
new company growth stageseed stageproject
Sarsia Innovation Venture Capital
Capital Squeeze
Incubator
De-merger of VC investment
Out source Seed
investment
2005
10
‘Bergen Model’ for commercialisation
new company growth stageseed stageproject
BTOSarsia Seed
FundSarsia Life
Science Fund
close cooperation
Sarsia Innovation as a facilitator for innovation
- independent decisions -A linkage point and facilitator in this process.
Investment decisions for the different phases are taken strictly independently.
Information flows freely to allow for smooth cooperation and company development.
11
Sarsia Innovation as - a facilitator for innovation
Sarsia Innovation as - a regional innovation network coordinator, which shall support and develop the innovative environment in the region.
Sarsia Innovation shall actively support regional initiatives for:
Incubator participant
Capital
infrastructure
Incubator,
Administrativesupport
Network
Strategy development
12
Specialized Network – Life Sciences
Different country strengths
• Norway
– Functional foods, diagnostics, med-tech, bio-marine
– Cancer registry, large cancer hospitals, access to clinical materials
• Sweden
– Pharma, diagnostics, med-tech
– Biotech innovation focus
– Life science private equity players
• Denmark
– Pharma and med-tech
– Several consolidating biotech clusters
• Finland
– Med tech, functional foods
– Innovation culture
– Strong sector growth
Helsinki-Turku
Blå grønn allianse
Medcoast Scandinavia
Medicon Valley
Stockholm-Uppsala
Bioteam south
Network partner
SLSF office
13
BTO shall coordinate the commercialization process, manage the projects and IPR and assist in the development towards “Proof of Concept” on behalf of the researcher and the research institutions .
BTO is a non-profit company owned by The University of Bergen, Institute of Marine Research and Bergen University Hospital.
Further more : – Promote commercial utilization of research
– Assist in attracting funding for further research and development
5 -> 8 Advisors
Funded by Norwegian Research Council and the owners
TTO deal-flow
14
Sarsia Seed Fund
Sector focusThe seed fund was established in 2006 with €45 million to invest in Norwegian early phase technology companies in the energy and biotechnology fields.
Fund structure30 to 40 seed companies between 2006 and 2013.Initially 0.5-1 MNOK and then up to 4 MNOK in progress-dependent instalments until divestment.
5 to 8 companies to become success stories.
InvestorsThe fund is backed by regional and national private investors, and the Norwegian government.
15
Sarsia Life Science Fund as
Sector focusThe venture fund was established in 2006 with €45 million to invest in companies in the Nordic region. The fund has a pure life sciences/ biotechnology focus:
- Diagnostics- Medical technology - Nutraceuticals - (Pharmaceuticals):
Fund structure10 to 15 venture companies before 2010, further 4-6 years in which follow-up investment
In each company, we look to invest 8-40 MNOK in instalments
The fund is backed by private investors
16
Capital, Shareholders and Management
Sarsia Life Science Fund as
Sarsia Seed Fund as
SarsiaVenture Management as
Sarsia Seed Management as
Sarsia Innovation as
Institutional investors
Private investors (75%)Public investors (25%)
Private / Public- partnership (50/50)
12%
Bergen Teknologi OverføringTTO
UiB IMR HB
projects
Public funding
17
Seed Fund structure and network…
Industrial/academic
advisory board
Dedicated management
FUNDcapitalM€45
Fund BoardInvestment & exit decisions
Portfolio companies
Joint networkand deal-flow
Support
Joint back office
18
How is it done at University of Bergen
• Sarsia Innovation
– Who is behind and why?
– Track record
• The early-stage gap
– Commercialisation chain
– What's missing an why?
• The development of the Bergen model commercialisation
– Sarsia faces the early-stage gap
– The ideal model ?
– The different players and their interface
– Different shareholders for different phase and corporate government
– Synergies